United States Patent RE48285: Scope and Claims Analysis for Crystalline N-(cyanomethyl)-4-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Dihydrochloride/Monohydrochloride Forms (I–III)
RE48285’s claim set is tightly focused on (1) three closely related salt/crystal regimes of one drug substance (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide) and (2) downstream protected product categories: crystalline solids, solid pharmaceutical compositions (including tablets), and a Janus kinase (JAK)-linked therapeutic use (myeloproliferative diseases and related hematologic indications). The claim architecture is typical of US reissue practice: strong chemical-identification anchors (exact Form identification plus XRPD/DSC/DVS characterization) combined with formulation and use claims, creating multiple infringement “entry points” for a would-be generic attempting to replicate the active.
What is RE48285 and what parts of the drug substance does it cover?
RE48285’s asserted core protection is crystalline drug substance for a specific active and salt forms. The claims enumerate three crystalline “forms” and require explicit identity constraints.
What compounds are explicitly in claim scope?
Claim 1 defines a compound “selected from the group” of three specific crystalline species (all the same molecular scaffold, differing by salt form, hydrate state, and crystal form designation):
- Form II:
N-(cyanomethyl)-4-(2-(4-morpholino)phenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate (spelled in the claim as “dihydrochloride monohydrate Form II”)
- Form I:
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous (“Form I”)
- Form III:
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous (“Form III”)
How much freedom does claim 1 allow?
Claim 1 is a closed set: it lists the only “selected from the group” species. A substitute that is the same base compound but with a different salt (different counterion), different hydrate level (e.g., dihydrate instead of monohydrate), or a different polymorph labeling would not meet claim 1 as written.
What do claims 2–16 actually require: “crystalline form” with analytical identity?
Claims 2–16 progressively narrow the subject matter from “crystalline form” to a specific Form II/Forms I/III supported by measurable analytical signatures. The key practical point for infringement is that the later claims incorporate specific unit-cell parameters and/or specific XRPD peak positions and/or DSC and DVS patterns.
Claims 2–8: Form II crystalline identity “tightened” by crystallographic and pattern evidence
-
Claim 2: “The compound of claim 1 in a crystalline form.”
This is a threshold claim category for crystallinity.
-
Claim 3: specifies Form II crystalline material:
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II
-
Claim 4: Form II must have a specific crystallographic unit cell at T = 100 K with a triclinic P-1 space group and given lattice parameters:
- a = 10.2837(6) Å
- b = 10.4981(6) Å
- c = 11.5143(7) Å
- α = 83.297(2)°
- β = 87.649(2)°
- γ = 67.445(2)°
-
Claims 5–8: Form II must match analytical fingerprints:
- Claim 5: XRPD pattern “substantially as set forth in FIG. 5”
- Claim 6: XRPD peaks at about 7.7°, 19.3°, 24.0°, 25.7°, and 29.6° 2-θ ± 0.2°
- Claim 7: DSC pattern “substantially as set forth in FIG. 8”
- Claim 8: DVS pattern “substantially as set forth in FIG. 14”
Practical enforcement implication: Claims 4 and 6 are the most “litigation-friendly” because they use explicit parameter values and numeric peak windows. Claims 5, 7, 8 are also strong but may require more interpretive evidence of “substantially as set forth” comparisons.
Claims 9–12: Form I anhydrous monohydrochloride with XRPD and DSC anchors
-
Claim 9: Crystalline Form I:
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form I
-
Claim 10: XRPD pattern “substantially as set forth in FIG. 6”
-
Claim 11: XRPD peaks at about 13.5°, 20.9°, 26.1°, 26.6°, and 28.3° 2-θ ± 0.2°
-
Claim 12: DSC pattern “substantially as set forth in FIG. 9”
Claims 13–16: Form III anhydrous monohydrochloride with XRPD and DSC anchors
-
Claim 13: Crystalline Form III:
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form III
-
Claim 14: XRPD pattern “substantially as set forth in FIG. 7”
-
Claim 15: XRPD peaks at about 12.7°, 14.6°, 17.8°, 19.7°, and 23.3° 2-θ ± 0.2°
-
Claim 16: DSC pattern “substantially as set forth in FIG. 10”
What formulations are protected: solid compositions and tablets (claims 17–22)?
The next infringement “layer” targets product dosage forms and performance.
Claim 17: pharmaceutical composition in solid form
- Claim 17: “A pharmaceutical composition comprising a compound of claim 1, wherein the pharmaceutical composition is in a solid form.”
This claim is broad as to excipients and tablet/capsule form factors (subject to later dependent claims).
Claims 18–20: specify Form II and tablet dosage form
- Claim 18: solid composition where the compound is Form II dihydrochloride monohydrate
- Claim 20: the pharmaceutical composition is in the form of a tablet
Claim 19: dose strength equivalence to free base amounts
Claim 19 ties tablet strength to a specific equivalence range by referencing amounts “equivalent to” the free base:
- amount equivalent to 50 mg, 100 mg, 150 mg, or 200 mg of free base.
The “equivalent to” framing matters for generic solids: it allows comparison through salt-to-free-base conversions, which can reduce design-around opportunities.
Claims 21–22: pharmacokinetic (PK) ranges as functional constraints
These claims attempt to lock in infringement through in vivo performance after single oral administration:
-
Claim 21: after a single oral administration, composition provides either:
- Cmax 260 to 405 ng/mL of the active, and/or
- AUCinf 2,057 to 3,214 ng·hr/mL,
including overlap where both Cmax and AUCinf fall within those ranges.
-
Claim 22: requires PK profile “substantially similar” to a benchmark dosage form comprising Form I anhydrous monohydrochloride in an amount equivalent to 300 mg free base.
Practical enforcement implication: PK-function claims can be powerful but also litigated on evidence quality (bioanalysis, study design, variability). The ranges and the benchmark reference create a measurable hook for comparing a defendant’s product performance.
What therapeutic method claims exist and what diseases are listed?
Claim 23: JAK-associated treatment method with enumerated myeloproliferative diseases
- Claim 23: “A method for the treatment of a disease associated with Janus Kinase (JAK)” comprising administering the claim 18 composition.
- Disease selection is limited to:
- thrombocythemia
- idiopathic myelofibrosis
- systemic mastocystosis (SM)
- myelodispiastic myelodysplastic syndrome (MDS)
- systemic mast cell disease (SMCD)
Scope note: This claim is not framed as “any JAK disease.” It is constrained to the listed conditions, and it depends on administering the specific composition of claim 18 (Form II in the solid formulation family).
What else is claimed: broad composition claims (claims 24–26)
Claims 24–26 are redundant and broad in category:
- Claims 24–26: pharmaceutical compositions comprising:
- a compound having “the formula” or a pharmaceutically acceptable salt
- plus a pharmaceutically acceptable excipient or diluent
Even though the claim text provided repeats the same language three times, the intent is clear: capture generic infringement that uses the same chemical entity (or salt) with standard excipients, without requiring the specific crystal/Form or performance elements.
How does RE48285’s claim scope map to typical generic “design-around” routes?
1) Changing polymorph or salt form
The set membership in claim 1 is closed for Form I vs Form II vs Form III crystal/salt regimes. Changing:
- hydrate state (monohydrate vs anhydrate),
- salt type (HCl vs other),
- or polymorphic form label
creates a path to argue non-infringement of claims 1, 3, 9, 13.
However, even if a generic avoids one Form, it still risks hitting broader composition claims 24–26 (depending on how “formula or pharmaceutically acceptable salt” is interpreted) and solid composition claim 17 (if crystallinity and identity are met).
2) Matching XRPD but not DSC or DVS (or vice versa)
Claims 4–8 and 10–16 distribute different analytical requirements across different dependent claims:
- some claims require XRPD peaks in numeric windows,
- others require DSC or DVS patterns “substantially” as in figures.
This yields multiple claim “lanes” for infringement proof. A generic trying to match XRPD yet differ in calorimetry may still land on an XRPD-dependent dependent claim.
3) Avoiding tablets and dose equivalence
Claim 20 limits one dependent claim to tablets. But claim 17 covers solid forms generally. If a generic sells capsules, it may avoid claim 20 but not necessarily claim 17. Claim 19 provides dose-equivalence ranges; it only binds products using those dose strengths “equivalent to” the referenced free base amounts.
4) Avoiding PK performance windows
Claims 21 and 22 are functionally defined through Cmax/AUCinf ranges and similarity to a benchmark Form I 300 mg-equivalent reference. A generic can attempt to argue its PK does not fall inside those numeric ranges or is not “substantially similar,” but the ranges create measurable targets for enforcement.
Patent landscape context for RE48285: what this claim set suggests about exclusivity strategy
RE48285 is a reissue directed to crystalline solid forms plus dependent product and use coverage. The claim structure typically indicates an exclusivity stack where:
- Drug substance exclusivity is anchored by polymorph/salt form claims with strong analytical identity features.
- Formulation exclusivity is built by solid composition and tablet claims tied to specific Form II.
- Clinical use exclusivity exists for JAK-related diseases via the method-of-treatment dependent claim.
- Functional performance is used to add a secondary barrier to generics through PK-based functional limitations.
In enforcement terms, it means the patent is designed to survive common generic attempts to select a different crystal Form while still targeting the claimed preferred regime through dependent formulations and use.
Key claim-by-claim scope table (what must be true for infringement)
| Claim |
Category |
What is required (high level) |
| 1 |
Drug substance |
One of: Form II dihydrochloride monohydrate, Form I monohydrochloride anhydrous, Form III monohydrochloride anhydrous |
| 2 |
Polymorph |
Compound of claim 1 must be crystalline |
| 3–8 |
Form II |
Form II identity; includes unit cell + XRPD peak list + DSC + DVS fingerprints |
| 9–12 |
Form I |
Form I identity; includes XRPD peak list + DSC fingerprint |
| 13–16 |
Form III |
Form III identity; includes XRPD peak list + DSC fingerprint |
| 17 |
Formulation |
Solid pharmaceutical composition containing compound of claim 1 |
| 18–19 |
Formulation |
Form II-specific solid; dose equivalence to free base 50/100/150/200 mg |
| 20 |
Dosage form |
Tablet |
| 21–22 |
PK function |
Cmax and/or AUCinf numeric ranges; PK similarity to a benchmark Form I 300 mg-equivalent reference |
| 23 |
Method-of-use |
JAK-associated diseases listed; administer claim 18 composition |
| 24–26 |
Broad composition |
Formula/salt + excipient/diluent composition |
Key Takeaways
- RE48285 is a crystalline-identity patent built around three explicit salt/hydrate/polymorph regimes (Form I, Form II monohydrate dihydrochloride, Form III) of a single named active.
- The claim set includes multiple analytic “proof hooks”: unit cell parameters at 100 K, numeric XRPD peak windows (with ±0.2°), plus DSC and DVS pattern requirements.
- Beyond substance, the patent extends to solid compositions, tablets, specific free-base-equivalent dose strengths, and two PK-functional dependent claims.
- A dependent method-of-use claim covers JAK-associated hematologic/myeloproliferative conditions (thrombocythemia, idiopathic myelofibrosis, SM, MDS, SMCD) when the administered product matches the Form II composition.
FAQs
1) Does RE48285 protect only Form II, or also Forms I and III?
It protects Forms I, II, and III through claim 1, with additional dependent claim sets for Form II (claims 3–8), Form I (claims 9–12), and Form III (claims 13–16).
2) Are XRPD peak lists the main infringement risk for generics?
They are a central risk because multiple dependent claims require specific XRPD peak positions with defined ±0.2° 2-θ windows (claims 6, 11, 15).
3) Can a generic avoid infringement by choosing a different polymorph label?
Avoiding a claimed Form label may avoid specific dependent claims (e.g., Form II in claims 3–8), but broad solid composition and formula/salt composition claims can still create infringement exposure depending on the exact identity and coverage interpretation.
4) Do the claims require tablet use for infringement?
No. Tablets are only required for claim 20. Claim 17 covers solid compositions generally.
5) What is the role of PK ranges in claim scope?
Claims 21–22 define infringement through in vivo PK outcomes after single oral dosing, using numeric Cmax and AUCinf ranges and a “substantially similar” benchmark comparison.
References (APA)
- United States Patent RE48285 (reissue patent document).
